Pfizer Inc. (PFE) Earnings Call Transcripts
Pfizer Inc.'s Latest Earnings Call - Q3 FY2026
Pfizer Inc. reported a strong third quarter for 2026, with revenues of $16.6 billion, reflecting a 7% operational growth in non-COVID products. Adjusted diluted EPS was $0.87, exceeding expectations and prompting management to raise full-year revenue guidance by $1.5 billion to a range of $62 billion to $64 billion. The company also raised its adjusted EPS guidance to a range of $2.95 to $3.05, indicating confidence in its ongoing operational execution and pipeline advancements.
Reported metrics
| Metric | Value |
|---|---|
| Revenue | $16.6 billion (beat) |
| Adjusted Diluted EPS | $0.87 (beat) |
| Adjusted Gross Margin | 77% |
| Full Year 2026 Revenue Guidance | $62 billion to $64 billion (positive) |
| Full Year 2026 Adjusted EPS Guidance | $2.95 to $3.05 (positive) |
| Operating Cash Flow | $8.8 billion |
Guidance from management
Pfizer raised its full-year 2026 revenue guidance to $62 billion to $64 billion and adjusted EPS guidance to $2.95 to $3.05, reflecting strong performance and confidence in future growth initiatives.
What management said
No. Thank you. Chris, would you like to cover the time lines of trispecific and, of course, the amylin and berobenatide questions. And then maybe Alexandre, you can speak a little bit about the commercial positioning.
Okay. Thank you very much. So the first on STAT6, potentially first-in-class oral STAT6 program. Thanks for the question. This is an area very important for us or the I&I portfolio. As we previously stated, we've adapted the program to incorporate some additional DDI studies. So we should give you a readout for the STAT6 this year. Regarding the amylin and berobenatide. As I stated earlier, the [ SOLIS-1 ] study is...
What analysts pressed on
Analysts raised concerns about the impact of declining COVID-19 product revenues on overall growth and questioned the sustainability of margins amid ongoing cost management efforts. There was also discussion on the competitive landscape for key products and the potential impact of regulatory changes on pricing dynamics.
Main topics on the call
- Revenue Growth in Non-COVID Products — Pfizer's non-COVID product revenues grew by 7% operationally, driven by strong performance in key brands. CEO Albert Bourla stated, "Our excellent commercial execution including 32% operational revenue growth in the quar...
- Pipeline Advancements and R&D Focus — Management highlighted significant progress in their R&D pipeline, with multiple Phase III trials underway and a focus on high-value therapeutic areas. Bourla noted, "We believe that we are on a pathway to the next stage...
- Guidance Increase — Pfizer raised its full-year 2026 revenue guidance by $1.5 billion and adjusted EPS guidance by $0.10, reflecting strong performance and confidence in future growth. CFO Cecile Guegan remarked, "This year's performance gi...
- Cost Management and Efficiency Initiatives — The company is on track to deliver $7.2 billion in net savings from cost improvement programs by the end of 2026, with an additional $2.5 billion expected from 2027 to 2029. Guegan stated, "We are improving operating eff...
Read the full Pfizer Inc. transcript (Q3 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About Pfizer Inc.
Pfizer Inc. (PFE) is a publicly listed company in the Pharmaceuticals industry, within the Health Care sector. It trades on NYSE and is based in US. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 116 calls on record spanning January 14, 2020 to November 3, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 116 Pfizer Inc. earnings call transcripts on record, spanning January 14, 2020 to November 3, 2026. Based on this history, Pfizer Inc. reports quarterly. The most recent call on file is dated November 3, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- PFE
- Exchange
- NYSE
- Country
- US
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Calls on record
- 116
- First call
- January 14, 2020
- Most recent
- November 3, 2026
- Reporting cadence
- quarterly